Podcast Episodes

Back to Search
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michae…

2 months, 3 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo
Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo

In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-appro…

2 months, 3 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Obsidian and Galera Therapeutics Enter Merger Agreement
Pharmaceutical Executive Daily: Obsidian and Galera Therapeutics Enter Merger Agreement

In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therape…

2 months, 4 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement

In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $74…

2 months, 4 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment

In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and T…

3 months ago

Short Long
View Episode
Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer
Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer

In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large s…

3 months ago

Short Long
View Episode
Why Branding is Pharma’s Most Undervalued Asset
Why Branding is Pharma’s Most Undervalued Asset

In this episode of Leading Edge With Ken Banta, The Vanguard Network founder and CEO is joined by branding strategist Andy Milligan, founding partne…

3 months ago

Short Long
View Episode
Pharmaceutical Executive Daily: Shionogi Receives a Contract Through BARDA's Project BioShield
Pharmaceutical Executive Daily: Shionogi Receives a Contract Through BARDA's Project BioShield

In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant …

3 months ago

Short Long
View Episode
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annua…

3 months ago

Short Long
View Episode
Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.
Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antib…

3 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us